Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

BACKGROUND: Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Tadaaki, Hirai, Soichi, Katayama, Yuki, Yoshimura, Akihiro, Shiotsu, Shinsuke, Watanabe, Satoshi, Kikuchi, Toshiaki, Hirose, Kazuki, Kubota, Yutaka, Chihara, Yusuke, Harada, Taishi, Tanimura, Keiko, Takeda, Takayuki, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488155/
https://www.ncbi.nlm.nih.gov/pubmed/30790471
http://dx.doi.org/10.1002/cam4.2037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488155/
https://www.ncbi.nlm.nih.gov/pubmed/30790471
http://dx.doi.org/10.1002/cam4.2037

Ejemplares similares